COMMUNIQUÉS West-GlobeNewswire

New Cardiovascular Device Approved in Japan: Elixir Medical Announces Regulatory Approval of DynamX® Coronary Bioadaptor System
14/09/2026
MILPITAS, Calif. and TOKYO , Sept. 14, 2026 (GLOBE NEWSWIRE) -- New Cardiovascular Device Approved in Japan: Elixir Medical Announces Regulatory Approval of DynamX® Coronary Bioadaptor System MILPITAS, Calif. and TOKYO [...]
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
14/09/2026
Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically significant genomic [...]
Parexel to Lead Sessions at DPHARM 2026 on AI, Talent and the Future of Clinical Operations
14/09/2026
CEO and other Parexel executive leaders will examine enterprise AI adoption, future workforce readiness and patient-first drug development RALEIGH, N.C., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Parexel, a leading global [...]
Communiqué de presse : Sanofi et Cheplapharm créent un nouveau partenariat stratégique autour des médicaments matures
14/09/2026
Sanofi et Cheplapharm créent un nouveau partenariat stratégique autour de s médicaments matures Paris, 14 septembre 2026. Sanofi et Cheplapharm, leader européen des médicaments matures, ont annoncé aujourd'hui leur [...]
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
14/09/2026
Sanofi and Cheplaphar m to create new strategic partnership i n mature medicines Paris , September 14, 2026 . Sanofi and Cheplapharm, a European leader in well-established medicines, today announced their intention to [...]
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
14/09/2026
President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET Management available for one-on-one meetings with investors during the conference CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE [...]
Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test
14/09/2026
DENVER, Sept. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is sending investors a signal that is impossible to ignore. The company's CEO, President and director, Amir F [...]
Novo Nordisk A/S - share repurchase programme
14/09/2026
Bagsværd, Denmark, 14 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
SafeSpace Global Announces First K-12 School Installation of Its AI-Powered Physical Safety Platform
14/09/2026
KNOXVILLE, Tenn., Sept. 14, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC) (“SafeSpace Global” or the “Company”), a publicly traded, applied multimodal AI-powered physical safety and security [...]
Catalyst MedTech Helps Imaging Providers See What’s Next in Nuclear Cardiology at ASNC 2026
14/09/2026
Company to Showcase Expanded Digirad® Cardiac SPECT Portfolio, PET/CT Solutions, Windows 11 Modernization and Nationwide Imaging Service PITTSBURGH, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Catalyst MedTech today announced it [...]
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
14/09/2026
Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s [...]
Children’s National receives $56.25 million Pediatric Prevention Network award
14/09/2026
Washington, DC, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Children’s National will receive $56.25 million over five years to help lead the Pediatric Prevention Network’s (PPN) work to strengthen pediatric disaster preparedness [...]
WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
14/09/2026
NANJING, China, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that updated Phase II data for opamtistomig (LBL-024), its [...]
Etienna Bio Completes FDA INTERACT Meeting for ETB-001
14/09/2026
LEAWOOD, Kan., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Etienna Bio, Inc. today announced that it completed an INTERACT meeting with the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) [...]
Sol y Vida Launches Nationwide Bilingual Telehealth Platform Built for Latino Communities
14/09/2026
Launching ahead of Hispanic Heritage Month, Latino-founded health platform provides English- and Spanish-language access to clinician-led weight management, metabolic health and wellness care LOS ANGELES, Sept. 14, 2026 [...]
FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
14/09/2026
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related [...]
Asimov Announces Cell Line Development Partnership with Sidewinder Therapeutics to Advance 4-Chain Bispecific Antibody for Solid Tumors
14/09/2026
As part of a multi-product collaboration, Asimov’s CHO Edge system enabled a high performance cell line for a first-in-class bispecific antibody, achieving clonal titers of over 10 g/L in a platform fed-batch process [...]
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
14/09/2026
Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for [...]
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
14/09/2026
CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric adverse events [...]

Pages